MYD88 and B-cell chronic lymphocytic leukemia: In contrast, MYD88 mutations were enriched in M-CLL, while no difference was seen when comparing early-stage versus late-stage patients or patients remaining untreated versus those requiring treatment (Fig. 1A and Supplementary Table S3).